Cargando…

Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives

Twelve aminoarylazocompounds (A–C) and 46 aryltriazene 7 derivatives (D–G) have been synthesized and evaluated in cell-based assays for cytotoxicity and antiviral activity against a panel of 10 RNA and DNA viruses. Eight aminoazocompounds and 27 aryltriazene derivatives exhibited antiviral activity,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tonelli, Michele, Vazzana, Iana, Tasso, Bruno, Boido, Vito, Sparatore, Fabio, Fermeglia, Maurizio, Paneni, Maria Silvia, Posocco, Paola, Pricl, Sabrina, Colla, Paolo La, Ibba, Cristina, Secci, Barbara, Collu, Gabriella, Loddo, Roberta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127694/
https://www.ncbi.nlm.nih.gov/pubmed/19482481
http://dx.doi.org/10.1016/j.bmc.2009.05.020
_version_ 1783516416256770048
author Tonelli, Michele
Vazzana, Iana
Tasso, Bruno
Boido, Vito
Sparatore, Fabio
Fermeglia, Maurizio
Paneni, Maria Silvia
Posocco, Paola
Pricl, Sabrina
Colla, Paolo La
Ibba, Cristina
Secci, Barbara
Collu, Gabriella
Loddo, Roberta
author_facet Tonelli, Michele
Vazzana, Iana
Tasso, Bruno
Boido, Vito
Sparatore, Fabio
Fermeglia, Maurizio
Paneni, Maria Silvia
Posocco, Paola
Pricl, Sabrina
Colla, Paolo La
Ibba, Cristina
Secci, Barbara
Collu, Gabriella
Loddo, Roberta
author_sort Tonelli, Michele
collection PubMed
description Twelve aminoarylazocompounds (A–C) and 46 aryltriazene 7 derivatives (D–G) have been synthesized and evaluated in cell-based assays for cytotoxicity and antiviral activity against a panel of 10 RNA and DNA viruses. Eight aminoazocompounds and 27 aryltriazene derivatives exhibited antiviral activity, sometimes of high level, against one or more viruses. A marked activity against BVDV and YFV was prevailing among the former compounds, while the latter type of compounds affected mainly CVB-2 and RSV. None of the active compounds inhibited the multiplication of HIV-1, VSV and VV. Arranged in order of decreasing potency and selectivity versus the host cell lines, the best compounds are the following; BVDV: 1 > 7 > 8 > 4; YFV: 7 > 5; CVB-2: 25 > 56 > 18; RSV: 14 > 20 > 55 > 38 > 18 > 19; HSV-1: 2. For these compounds the EC(50) ranged from 1.6 μM (1) to 12 μM (18), and the S. I. from 19.4 (1) to 4.2 (2). Thus the aminoarylazo and aryltriazene substructures appear as interesting molecular component for developing antiviral agents against ss RNA viruses, particularly against RSV and BVDV, which are important human and veterinary pathogens. Finally, molecular modeling investigations indicated that compounds of structure A–C, active against BVDV, could work targeting the viral RNA-dependent RNA-polymerase (RdRp), having been observed a good agreement between the trends of the estimated IC(50) and the experimental EC(50) values.
format Online
Article
Text
id pubmed-7127694
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71276942020-04-08 Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives Tonelli, Michele Vazzana, Iana Tasso, Bruno Boido, Vito Sparatore, Fabio Fermeglia, Maurizio Paneni, Maria Silvia Posocco, Paola Pricl, Sabrina Colla, Paolo La Ibba, Cristina Secci, Barbara Collu, Gabriella Loddo, Roberta Bioorg Med Chem Article Twelve aminoarylazocompounds (A–C) and 46 aryltriazene 7 derivatives (D–G) have been synthesized and evaluated in cell-based assays for cytotoxicity and antiviral activity against a panel of 10 RNA and DNA viruses. Eight aminoazocompounds and 27 aryltriazene derivatives exhibited antiviral activity, sometimes of high level, against one or more viruses. A marked activity against BVDV and YFV was prevailing among the former compounds, while the latter type of compounds affected mainly CVB-2 and RSV. None of the active compounds inhibited the multiplication of HIV-1, VSV and VV. Arranged in order of decreasing potency and selectivity versus the host cell lines, the best compounds are the following; BVDV: 1 > 7 > 8 > 4; YFV: 7 > 5; CVB-2: 25 > 56 > 18; RSV: 14 > 20 > 55 > 38 > 18 > 19; HSV-1: 2. For these compounds the EC(50) ranged from 1.6 μM (1) to 12 μM (18), and the S. I. from 19.4 (1) to 4.2 (2). Thus the aminoarylazo and aryltriazene substructures appear as interesting molecular component for developing antiviral agents against ss RNA viruses, particularly against RSV and BVDV, which are important human and veterinary pathogens. Finally, molecular modeling investigations indicated that compounds of structure A–C, active against BVDV, could work targeting the viral RNA-dependent RNA-polymerase (RdRp), having been observed a good agreement between the trends of the estimated IC(50) and the experimental EC(50) values. Elsevier Ltd. 2009-07-01 2009-05-15 /pmc/articles/PMC7127694/ /pubmed/19482481 http://dx.doi.org/10.1016/j.bmc.2009.05.020 Text en Copyright © 2009 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Tonelli, Michele
Vazzana, Iana
Tasso, Bruno
Boido, Vito
Sparatore, Fabio
Fermeglia, Maurizio
Paneni, Maria Silvia
Posocco, Paola
Pricl, Sabrina
Colla, Paolo La
Ibba, Cristina
Secci, Barbara
Collu, Gabriella
Loddo, Roberta
Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives
title Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives
title_full Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives
title_fullStr Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives
title_full_unstemmed Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives
title_short Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives
title_sort antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127694/
https://www.ncbi.nlm.nih.gov/pubmed/19482481
http://dx.doi.org/10.1016/j.bmc.2009.05.020
work_keys_str_mv AT tonellimichele antiviralandcytotoxicactivitiesofaminoarylazocompoundsandaryltriazenederivatives
AT vazzanaiana antiviralandcytotoxicactivitiesofaminoarylazocompoundsandaryltriazenederivatives
AT tassobruno antiviralandcytotoxicactivitiesofaminoarylazocompoundsandaryltriazenederivatives
AT boidovito antiviralandcytotoxicactivitiesofaminoarylazocompoundsandaryltriazenederivatives
AT sparatorefabio antiviralandcytotoxicactivitiesofaminoarylazocompoundsandaryltriazenederivatives
AT fermegliamaurizio antiviralandcytotoxicactivitiesofaminoarylazocompoundsandaryltriazenederivatives
AT panenimariasilvia antiviralandcytotoxicactivitiesofaminoarylazocompoundsandaryltriazenederivatives
AT posoccopaola antiviralandcytotoxicactivitiesofaminoarylazocompoundsandaryltriazenederivatives
AT priclsabrina antiviralandcytotoxicactivitiesofaminoarylazocompoundsandaryltriazenederivatives
AT collapaolola antiviralandcytotoxicactivitiesofaminoarylazocompoundsandaryltriazenederivatives
AT ibbacristina antiviralandcytotoxicactivitiesofaminoarylazocompoundsandaryltriazenederivatives
AT seccibarbara antiviralandcytotoxicactivitiesofaminoarylazocompoundsandaryltriazenederivatives
AT collugabriella antiviralandcytotoxicactivitiesofaminoarylazocompoundsandaryltriazenederivatives
AT loddoroberta antiviralandcytotoxicactivitiesofaminoarylazocompoundsandaryltriazenederivatives